<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Evaluation of secondary hypertension</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Evaluation of secondary hypertension</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Evaluation of secondary hypertension</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Stephen Textor, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">George L Bakris, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">William J Elliott, MD, PhD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John P Forman, MD, MSc</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Sep 08, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The evaluation of a patient with hypertension depends upon the likely cause and the degree of difficulty in achieving acceptable blood pressure control since many forms of secondary hypertension lead to "treatment-resistant" hypertension [<a href="#rid1">1</a>]. Patients likely to have primary (idiopathic or "essential") hypertension undergo a relatively limited evaluation because extensive laboratory testing is usually of little value. (See  <a class="medical medical_review" href="/z/d/html/3849.html" rel="external">"Initial evaluation of adults with hypertension"</a>.)</p><p>By contrast, patients who have clinical clues suggesting the possible presence of secondary hypertension should undergo a more extensive evaluation. If secondary hypertension is present, the most effective treatment strategy often is one that is focused upon the specific mechanism underlying the hypertension. In addition, some of these disorders can be cured, leading to partial or complete normalization of the blood pressure.</p><p>Because it is not cost effective to perform a complete evaluation for secondary hypertension in every hypertensive patient, it is important to be aware of the clinical clues that suggest secondary hypertension. The identification of patients who should undergo an evaluation for secondary hypertension will be reviewed here. Testing methods for renovascular hypertension and treatment of unilateral and bilateral atherosclerotic renal artery stenosis are discussed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3825.html" rel="external">"Establishing the diagnosis of renovascular hypertension"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3834.html" rel="external">"Treatment of unilateral atherosclerotic renal artery stenosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3836.html" rel="external">"Treatment of bilateral atherosclerotic renal artery stenosis or stenosis to a solitary functioning kidney"</a>.)</p><p></p><p class="headingAnchor" id="H2"><span class="h1">GENERAL CLINICAL CLUES</span><span class="headingEndMark"> — </span>There are a number of general clinical clues that, in isolation or in combination, are suggestive of secondary hypertension  (<a class="graphic graphic_table graphicRef56130" href="/z/d/graphic/56130.html" rel="external">table 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Severe or resistant hypertension. Resistant hypertension is defined as the persistence of hypertension despite concurrent use of adequate doses of three antihypertensive agents from different classes, including a diuretic. (See  <a class="medical medical_review" href="/z/d/html/3818.html" rel="external">"Definition, risk factors, and evaluation of resistant hypertension", section on 'Definitions'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A recent rise or increased lability in blood pressure developing in a patient with previously stable values.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Age less than 30 years in patients without obesity, with a negative family history of hypertension, and no other risk factors for hypertension.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Malignant or accelerated hypertension (eg, patients with severe hypertension and signs of end-organ damage such as retinal hemorrhages or papilledema, heart failure, neurologic disturbance, or acute kidney injury). (See  <a class="medical medical_review" href="/z/d/html/3833.html" rel="external">"Moderate to severe hypertensive retinopathy and hypertensive encephalopathy in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hypertension associated with electrolyte disorders including hypokalemia and metabolic alkalosis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Proven age of onset before puberty.</p><p></p><p>In addition to these clues, there are other findings that specifically suggest renovascular or other forms of secondary hypertension, as described in the following sections.</p><p class="headingAnchor" id="H3"><span class="h1">CLINICAL CLUES FOR RENOVASCULAR HYPERTENSION</span><span class="headingEndMark"> — </span>Renovascular hypertension is among the most common potentially correctable causes of secondary hypertension. The incidence varies with the clinical setting. It probably occurs in less than 1 percent of patients with mild hypertension [<a href="#rid2">2</a>]. By comparison, a substantial proportion of patients with moderate to severe hypertensive retinopathy and/or other hypertensive target organ injury have renal artery stenosis. Renal artery stenosis can be detected in many individuals with other manifestations of atherosclerosis, such as coronary artery disease (10 to 14 percent) and peripheral arterial and aortic disease (24 to 35 percent) [<a href="#rid3">3</a>].</p><p>For reasons that are not well understood, renovascular disease is less commonly identified in Black patients [<a href="#rid4">4,5</a>]. As an example, the prevalence of renal artery stenosis in high-risk patients with severe or refractory hypertension was 27 to 45 percent in White patients, compared with 8 to 19 percent in Black patients [<a href="#rid4">4</a>]. A more extreme disparity was found in a retrospective review of all patients diagnosed with renal artery stenosis at a single center, 95 percent of who were White patients [<a href="#rid5">5</a>]. However, two studies that prospectively screened individuals with or without clinical clues for renovascular hypertension found similar rates of renal artery stenosis in Black and White patients [<a href="#rid6">6,7</a>]. Referral bias is a possible explanation for this discrepancy, given that Black patients diagnosed with renal artery stenosis were more likely than White patients to have severe or refractory hypertension and a history of stroke or myocardial infarction [<a href="#rid5">5</a>].</p><p>There are a variety of findings associated with a higher likelihood of hypertension being secondary to renovascular disease. The 2017 American Heart Association hypertension guidelines and the 2014 consensus statement from the Society for Cardiovascular Angiography and Interventions propose that diagnostic testing for renal artery stenosis could be performed in the following settings, assuming that a revascularization procedure would be considered if renovascular disease were detected [<a href="#rid8">8,9</a>]. As with other vascular diseases, long-term management of these patients can be affected by the potential for progressive vascular occlusion. Recommendations for selecting patients for renal artery revascularization are presented elsewhere. (See  <a class="medical medical_review" href="/z/d/html/3834.html" rel="external">"Treatment of unilateral atherosclerotic renal artery stenosis", section on 'General approach to therapy'</a> and  <a class="medical medical_review" href="/z/d/html/3836.html" rel="external">"Treatment of bilateral atherosclerotic renal artery stenosis or stenosis to a solitary functioning kidney", section on 'General approach to therapy'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>The general, clinical clues for any cause of secondary hypertension, as cited in the preceding section. (See <a class="local">'General clinical clues'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Onset of severe hypertension (blood pressure ≥180 mmHg systolic and/or 120 mmHg diastolic) after the age of 55 years.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Unexplained deterioration of kidney function during antihypertensive therapy, especially an acute and sustained elevation in the serum creatinine concentration by more than 50 percent that occurs within one week of instituting therapy with an angiotensin-converting enzyme (ACE) inhibitor, angiotensin II receptor blocker (ARB), or direct renin inhibitor. (See  <a class="medical medical_review" href="/z/d/html/3873.html" rel="external">"Renal effects of ACE inhibitors in hypertension"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Severe hypertension in patients with diffuse atherosclerosis, particularly those over age 50. The relationship between atherosclerotic renal artery stenosis and atherosclerosis at other sites (eg, coronary, peripheral arterial) is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/3841.html" rel="external">"Chronic kidney disease resulting from atherosclerotic renal artery stenosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Severe hypertension in a patient with an unexplained atrophic kidney or asymmetry in kidney sizes of &gt;1.5 cm. A unilateral small kidney (≤9 cm) has a 75 percent association with the presence of large vessel occlusive disease.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Severe hypertension in patients with recurrent episodes of acute (flash) pulmonary edema or refractory heart failure with impaired kidney function [<a href="#rid10">10</a>]. In a series of 55 patients with renovascular hypertension, for example, 23 percent had recurrent episodes of pulmonary edema requiring hospitalization. Flash pulmonary edema was more common in patients with bilateral compared with unilateral renal artery stenosis. The factors that contribute to acute decompensation include a hypertension-induced increase in afterload, inability of a hypertrophied left ventricle to relax in diastole (ie, diastolic with or without systolic dysfunction), sodium retention due to activation of the renin-angiotensin-aldosterone system, and associated kidney dysfunction [<a href="#rid11">11,12</a>]. Registry data from the United Kingdom indicate that patients with episodes of pulmonary edema and renal artery stenosis have reduced mortality after successful renal revascularization [<a href="#rid13">13</a>]. (See  <a class="medical medical_review" href="/z/d/html/3497.html" rel="external">"Approach to diagnosis and evaluation of acute decompensated heart failure in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A systolic-diastolic abdominal bruit that lateralizes to one side. This finding has a sensitivity of approximately 40 percent (and is therefore absent in many patients) but has a specificity as high as 99 percent [<a href="#rid14">14</a>]. Systolic bruits alone are more sensitive but less specific [<a href="#rid14">14</a>]. The patient should be supine, moderate pressure should be placed, using the diaphragm of the stethoscope, and auscultation should be performed in the epigastrium and all four abdominal quadrants.</p><p></p><p>In summary, radiologic testing to confirm the presence of renal artery stenosis <strong>may</strong> be indicated in patients for whom the history is suggestive (based upon a general assessment of clinical risk factors) <strong>and</strong> in whom a corrective procedure will be performed if renovascular disease is detected or progresses [<a href="#rid15">15</a>]. There is little value and potential harm from radiologic testing if the patient is not a candidate for a corrective procedure. Imaging methods for renovascular hypertension, and how one makes the choice between medical and interventional therapy in such patients over time, are discussed elsewhere:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3825.html" rel="external">"Establishing the diagnosis of renovascular hypertension"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3834.html" rel="external">"Treatment of unilateral atherosclerotic renal artery stenosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3836.html" rel="external">"Treatment of bilateral atherosclerotic renal artery stenosis or stenosis to a solitary functioning kidney"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3826.html" rel="external">"Treatment of fibromuscular dysplasia of the renal arteries"</a>.)</p><p></p><p class="headingAnchor" id="H4"><span class="h1">CLUES FOR OTHER MAJOR FORMS OF SECONDARY HYPERTENSION</span><span class="headingEndMark"> — </span>Other causes of secondary hypertension also must be excluded in the appropriate settings  (<a class="graphic graphic_table graphicRef56130" href="/z/d/graphic/56130.html" rel="external">table 1</a>).</p><p class="headingAnchor" id="H5"><span class="h2">Primary kidney disease</span><span class="headingEndMark"> — </span>The presence of primary kidney disease is suggested by an elevated serum creatinine concentration and/or an abnormal urinalysis. (See  <a class="medical medical_review" href="/z/d/html/3872.html" rel="external">"Overview of hypertension in acute and chronic kidney disease"</a>.)</p><p class="headingAnchor" id="H3174297"><span class="h2">Primary aldosteronism</span><span class="headingEndMark"> — </span>The main clinical clue suggestive of primary aldosteronism is otherwise unexplained or easily provoked hypokalemia due to urinary potassium wasting. However, evaluation for primary aldosteronism is rarely performed in such patients; in a cohort of 26,533 patients from Canada, for example, only 1.6 percent of patients with hypertension and hypokalemia underwent screening over a two-year period [<a href="#rid16">16</a>]. Identification of excess aldosterone is warranted both for targeted blood pressure reduction and to avoid other adverse effects of aldosterone [<a href="#rid17">17</a>]. </p><p>More than one-half of patients have a normal serum potassium concentration at detection, and, therefore, nearly <strong>all</strong> patients with suspected secondary hypertension should be evaluated for primary aldosteronism, as should patients with drug-resistant hypertension. Despite this recommendation, testing for primary aldosteronism is uncommon among such patients; as an example, in a cohort of 18,908 patients with apparent resistant hypertension, just 795 were screened (4.2 percent) [<a href="#rid18">18</a>]. </p><p>Primary aldosteronism should also be suspected in the presence of slight hypernatremia and/or hypertension with an adrenal incidentaloma. Measurement of the ratio of the plasma aldosterone concentration to plasma renin activity can help identify such patients [<a href="#rid19">19</a>] although inappropriate elevation of aldosterone is also a common feature in patients with obesity [<a href="#rid20">20</a>]. (See  <a class="medical medical_review" href="/z/d/html/138.html" rel="external">"Diagnosis of primary aldosteronism"</a> and  <a class="medical medical_review" href="/z/d/html/153.html" rel="external">"Evaluation and management of the adrenal incidentaloma", section on 'Aldosteronomas'</a>.)</p><p class="headingAnchor" id="H561352260"><span class="h2">Sleep apnea syndrome</span><span class="headingEndMark"> — </span>The sleep apnea syndrome is most commonly identified in males with obesity who snore loudly while asleep. These patients have repeated apneic episodes at night due to passive collapse of the pharyngeal muscles during inspiration, such that the airway becomes temporarily occluded from the apposition of the tongue and soft palate against the posterior oropharynx. A variety of other symptoms may be seen, including headache, daytime somnolence and fatigue, morning confusion with difficulty in concentration, personality changes, depression, persistent systemic hypertension, and potentially life-threatening cardiac arrhythmias. (See  <a class="medical medical_review" href="/z/d/html/7706.html" rel="external">"Clinical presentation and diagnosis of obstructive sleep apnea in adults"</a>.)</p><p>Patients with obstructive sleep apnea often retain sodium and fail to respond optimally to antihypertensive drug therapy [<a href="#rid21">21</a>]. Correction of the sleep apnea may improve blood pressure control and improve the response to antihypertensive drug therapy [<a href="#rid22">22</a>]. (See  <a class="medical medical_review" href="/z/d/html/7705.html" rel="external">"Obstructive sleep apnea and cardiovascular disease in adults", section on 'Hypertension'</a>.)</p><p class="headingAnchor" id="H115977394"><span class="h1">LESS COMMON FORMS OF SECONDARY HYPERTENSION</span></p><p class="headingAnchor" id="H6"><span class="h2">Oral contraceptives</span><span class="headingEndMark"> — </span>Oral contraceptives often raise the blood pressure within the normal range but can induce overt hypertension. (See  <a class="medical medical_review" href="/z/d/html/3827.html" rel="external">"Contraception: Hormonal contraception and blood pressure"</a>.)</p><p class="headingAnchor" id="H7"><span class="h2">Pheochromocytoma</span><span class="headingEndMark"> — </span>Pheochromocytoma should be suspected if there are paroxysmal elevations in blood pressure (which may be superimposed upon stable chronic hypertension), particularly if associated with the triad of headache (usually pounding), palpitations, and sweating. Patients identified with pheochromocytoma are rarely asymptomatic. In addition, patients with drug-resistant hypertension and those with an adrenal incidentaloma should be evaluated for pheochromocytoma. Other patients with suspected secondary hypertension who do not have these symptoms or an adrenal incidentaloma should not be evaluated for this rare cause of hypertension. (See  <a class="medical medical_review" href="/z/d/html/130.html" rel="external">"Clinical presentation and diagnosis of pheochromocytoma"</a> and  <a class="medical medical_review" href="/z/d/html/153.html" rel="external">"Evaluation and management of the adrenal incidentaloma", section on 'Pheochromocytoma'</a>.)</p><p class="headingAnchor" id="H9"><span class="h2">Cushing's syndrome</span><span class="headingEndMark"> — </span>Cushing's syndrome (including that due to glucocorticoid administration) is usually suggested by the classic physical findings of Cushingoid facies, central adiposity, proximal muscle weakness, and ecchymoses. However, Cushing's or subclinical Cushing's syndrome should also be suspected in patients with drug-resistant hypertension who have an adrenal incidentaloma. In the absence of such clues, patients with suspected secondary hypertension do not require evaluation for Cushing's syndrome. (See  <a class="medical medical_review" href="/z/d/html/143.html" rel="external">"Epidemiology and clinical manifestations of Cushing syndrome"</a> and  <a class="medical medical_review" href="/z/d/html/153.html" rel="external">"Evaluation and management of the adrenal incidentaloma", section on 'Subclinical Cushing syndrome'</a>.)</p><p class="headingAnchor" id="H11"><span class="h2">Coarctation of the aorta</span><span class="headingEndMark"> — </span>Coarctation of the aorta (or pediatric midaortic syndrome) is one of the major causes of secondary hypertension in young children but may first be detected in adulthood  (<a class="graphic graphic_diagnosticimage graphicRef70656 graphicRef79548" href="/z/d/graphic/70656.html" rel="external">image 1A-B</a>). The classic findings are hypertension in the upper extremities, diminished or delayed femoral pulses ("brachial-femoral delay"), and low or unobtainable arterial blood pressure in the lower extremities. In addition, a prominent "to-and-fro machinery murmur" from the aorta may be heard over the posterior chest.</p><p>Patient age, the site of origin of the left subclavian artery, and the severity of the coarctation affect the pattern of blood pressure findings. As an example, the origin of the left subclavian artery is just distal to the coarctation in some patients; in this setting, the left brachial pulse is diminished compared with the right and equal to the femoral pulse. (See  <a class="medical medical_review" href="/z/d/html/5760.html" rel="external">"Clinical manifestations and diagnosis of coarctation of the aorta"</a>.)</p><p>Based upon the 2013 European Societies of Hypertension and Cardiology (ESH/ESC) report on hypertension and the 2008 American College of Cardiology/American Heart Association (ACC/AHA) guidelines for adults with congenital heart disease, patients with hypertension should be evaluated for possible coarctation of the aorta [<a href="#rid23">23,24</a>]. This involves palpating the brachial and femoral pulses simultaneously to assess amplitude and timing, looking for diminished arterial pulses and brachial-femoral delay. In addition, the ACC/AHA guidelines recommended measurement of supine bilateral arm (brachial artery) blood pressures and prone right or left supine leg (popliteal artery) blood pressures to search for differential pressures. (See  <a class="medical medical_review" href="/z/d/html/1077.html" rel="external">"Examination of the arterial pulse", section on 'Unequal or delayed pulses'</a>.)</p><p class="headingAnchor" id="H12"><span class="h2">Other endocrine disorders</span><span class="headingEndMark"> — </span>Hypertension may be associated with hypothyroidism, which may be suspected because of suggestive symptoms or an elevated serum thyroid-stimulating hormone level (measured as part of the evaluation of resistant hypertension), or primary hyperparathyroidism. The latter is most often suspected because of otherwise unexplained hypercalcemia, which may affect vascular reactivity, day-night blood pressure regulation, and kidney function [<a href="#rid25">25-27</a>]. (See  <a class="medical medical_review" href="/z/d/html/7893.html" rel="external">"Diagnosis of and screening for hypothyroidism in nonpregnant adults"</a> and  <a class="medical medical_review" href="/z/d/html/2029.html" rel="external">"Primary hyperparathyroidism: Diagnosis, differential diagnosis, and evaluation"</a> and  <a class="medical medical_review" href="/z/d/html/832.html" rel="external">"Clinical manifestations of hypercalcemia"</a>.)</p><p class="headingAnchor" id="H800315538"><span class="h2">Chemotherapeutic agents</span><span class="headingEndMark"> — </span>A growing number of chemotherapeutic agents result in secondary hypertension and kidney injury. Problematic agents include those associated with microvascular injury (such as thrombotic microangiopathy from <a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">gemcitabine</a>). The newer classes of antiangiogenic agents that inhibit vascular endothelial growth factor (VEGF) signaling pathways regularly produce a rise in arterial pressure, often associated with proteinuria and kidney dysfunction [<a href="#rid28">28,29</a>]. Second-generation androgen deprivation therapy such as <a class="drug drug_general" data-topicid="16083" href="/z/d/drug information/16083.html" rel="external">abiraterone</a> leads to accumulation of mineralocorticoid-active metabolites that can induce or worsen hypertension [<a href="#rid30">30</a>]. (See  <a class="medical medical_review" href="/z/d/html/98720.html" rel="external">"Drug-induced thrombotic microangiopathy (DITMA)"</a> and  <a class="medical medical_review" href="/z/d/html/114914.html" rel="external">"Nephrotoxicity of molecularly targeted agents and immunotherapy"</a> and  <a class="medical medical_review" href="/z/d/html/2834.html" rel="external">"Nephrotoxicity of chemotherapy and other cytotoxic agents"</a>.)</p><p class="headingAnchor" id="H1531682244"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/109601.html" rel="external">"Society guideline links: Hypertension in adults"</a>.)</p><p class="headingAnchor" id="H13"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/17167.html" rel="external">"Patient education: Renovascular hypertension (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/z/d/html/4416.html" rel="external">"Patient education: High blood pressure in adults (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/z/d/html/4424.html" rel="external">"Patient education: High blood pressure treatment in adults (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/z/d/html/4415.html" rel="external">"Patient education: High blood pressure, diet, and weight (Beyond the Basics)"</a>).</p><p></p><p class="headingAnchor" id="H9686035"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Selecting patients for evaluation</strong> – It is not cost effective to perform a complete evaluation for secondary hypertension in every hypertensive patient. Thus, it is important to be aware of the clinical clues that suggest secondary hypertension  (<a class="graphic graphic_table graphicRef56130" href="/z/d/graphic/56130.html" rel="external">table 1</a>). (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>General clues suggesting secondary hypertension</strong> – There are a number of general, clinical clues that are suggestive of secondary hypertension  (<a class="graphic graphic_table graphicRef56130" href="/z/d/graphic/56130.html" rel="external">table 1</a>) (see <a class="local">'General clinical clues'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Severe or resistant hypertension. Resistant hypertension is defined as the persistence of hypertension despite concurrent use of adequate doses of three antihypertensive agents from different classes, including a diuretic.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>An acute rise in blood pressure developing in a patient with previously stable values.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Age less than 30 years in patients without obesity, a negative family history of hypertension, and no other risk factors for hypertension.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Malignant or accelerated hypertension (eg, patients with severe hypertension and signs of end-organ damage such as retinal hemorrhages or papilledema, heart failure, neurologic disturbance, or acute kidney injury).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Proven age of onset before puberty.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clues suggesting specific causes of secondary hypertension</strong> – In addition to these clues, there are other findings that specifically suggest renovascular hypertension, such as an acute sustained elevation in the serum creatinine by more than 50 percent within a week of instituting therapy with an angiotensin-converting enzyme (ACE) inhibitor, angiotensin II receptor blocker (ARB), or direct renin inhibitor, severe hypertension in a patient with an unexplained atrophic kidney or asymmetry in kidney sizes, severe hypertension in a patient with recurrent episodes of acute (flash) pulmonary edema or refractory heart failure with impaired kidney function, and severe hypertension in conjunction with a systolic-diastolic abdominal bruit that lateralizes to one side. (See <a class="local">'Clinical clues for renovascular hypertension'</a> above.)</p><p></p><p class="bulletIndent1">Other causes of secondary hypertension, including primary kidney disease, primary aldosteronism, use of oral contraceptives, pheochromocytoma, Cushing's syndrome, sleep apnea syndrome, and coarctation of the aorta, must also be excluded in the appropriate settings  (<a class="graphic graphic_table graphicRef56130" href="/z/d/graphic/56130.html" rel="external">table 1</a>). (See <a class="local">'Clues for other major forms of secondary hypertension'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation 2008; 117:e510.</a></li><li><a class="nounderline abstract_t">Lewin A, Blaufox MD, Castle H, et al. Apparent prevalence of curable hypertension in the Hypertension Detection and Follow-up Program. Arch Intern Med 1985; 145:424.</a></li><li><a class="nounderline abstract_t">Textor SC, Lerman L. Renovascular hypertension and ischemic nephropathy. Am J Hypertens 2010; 23:1159.</a></li><li><a class="nounderline abstract_t">Davis BA, Crook JE, Vestal RE, Oates JA. Prevalence of renovascular hypertension in patients with grade III or IV hypertensive retinopathy. N Engl J Med 1979; 301:1273.</a></li><li><a class="nounderline abstract_t">Novick AC, Zaki S, Goldfarb D, Hodge EE. Epidemiologic and clinical comparison of renal artery stenosis in black patients and white patients. J Vasc Surg 1994; 20:1.</a></li><li><a class="nounderline abstract_t">Hansen KJ, Edwards MS, Craven TE, et al. Prevalence of renovascular disease in the elderly: a population-based study. J Vasc Surg 2002; 36:443.</a></li><li><a class="nounderline abstract_t">Svetkey LP, Kadir S, Dunnick NR, et al. Similar prevalence of renovascular hypertension in selected blacks and whites. Hypertension 1991; 17:678.</a></li><li><a class="nounderline abstract_t">Rooke TW, Hirsch AT, Misra S, et al. 2011 ACCF/AHA Focused Update of the Guideline for the Management of Patients With Peripheral Artery Disease (updating the 2005 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2011; 58:2020.</a></li><li><a class="nounderline abstract_t">Parikh SA, Shishehbor MH, Gray BH, et al. SCAI expert consensus statement for renal artery stenting appropriate use. Catheter Cardiovasc Interv 2014; 84:1163.</a></li><li><a class="nounderline abstract_t">Kane GC, Xu N, Mistrik E, et al. Renal artery revascularization improves heart failure control in patients with atherosclerotic renal artery stenosis. Nephrol Dial Transplant 2010; 25:813.</a></li><li><a class="nounderline abstract_t">Gandhi SK, Powers JC, Nomeir AM, et al. The pathogenesis of acute pulmonary edema associated with hypertension. N Engl J Med 2001; 344:17.</a></li><li><a class="nounderline abstract_t">Messerli FH, Bangalore S, Makani H, et al. Flash pulmonary oedema and bilateral renal artery stenosis: the Pickering syndrome. Eur Heart J 2011; 32:2231.</a></li><li><a class="nounderline abstract_t">Ritchie J, Green D, Chrysochou C, et al. High-risk clinical presentations in atherosclerotic renovascular disease: prognosis and response to renal artery revascularization. Am J Kidney Dis 2014; 63:186.</a></li><li><a class="nounderline abstract_t">Turnbull JM. The rational clinical examination. Is listening for abdominal bruits useful in the evaluation of hypertension? JAMA 1995; 274:1299.</a></li><li><a class="nounderline abstract_t">Bhalla V, Textor SC, Beckman JA, et al. Revascularization for Renovascular Disease: A Scientific Statement From the American Heart Association. Hypertension 2022; 79:e128.</a></li><li><a class="nounderline abstract_t">Hundemer GL, Imsirovic H, Vaidya A, et al. Screening Rates for Primary Aldosteronism Among Individuals With Hypertension Plus Hypokalemia: A Population-Based Retrospective Cohort Study. Hypertension 2022; 79:178.</a></li><li><a class="nounderline abstract_t">Reincke M, Bancos I, Mulatero P, et al. Diagnosis and treatment of primary aldosteronism. Lancet Diabetes Endocrinol 2021; 9:876.</a></li><li><a class="nounderline abstract_t">Zekarias K, Tessier KM. Screening Rate for Primary Aldosteronism Among Patients With Apparent Treatment-Resistant Hypertension: Retrospective Analysis of Current Practice. Endocr Pract 2022; 28:271.</a></li><li><a class="nounderline abstract_t">Nishizaka MK, Pratt-Ubunama M, Zaman MA, et al. Validity of plasma aldosterone-to-renin activity ratio in African American and white subjects with resistant hypertension. Am J Hypertens 2005; 18:805.</a></li><li><a class="nounderline abstract_t">Goodfriend TL, Calhoun DA. Resistant hypertension, obesity, sleep apnea, and aldosterone: theory and therapy. Hypertension 2004; 43:518.</a></li><li><a class="nounderline abstract_t">Logan AG, Perlikowski SM, Mente A, et al. High prevalence of unrecognized sleep apnoea in drug-resistant hypertension. J Hypertens 2001; 19:2271.</a></li><li><a class="nounderline abstract_t">Somers VK, White DP, Amin R, et al. Sleep apnea and cardiovascular disease: an American Heart Association/American College of Cardiology Foundation Scientific Statement from the American Heart Association Council for High Blood Pressure Research Professional Education Committee, Council on Clinical Cardiology, Stroke Council, and Council on Cardiovascular Nursing. J Am Coll Cardiol 2008; 52:686.</a></li><li><a class="nounderline abstract_t">Warnes CA, Williams RG, Bashore TM, et al. ACC/AHA 2008 Guidelines for the Management of Adults with Congenital Heart Disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to develop guidelines on the management of adults with congenital heart disease). Circulation 2008; 118:e714.</a></li><li><a class="nounderline abstract_t">Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013; 31:1281.</a></li><li><a class="nounderline abstract_t">Streeten DH, Anderson GH Jr, Howland T, et al. Effects of thyroid function on blood pressure. Recognition of hypothyroid hypertension. Hypertension 1988; 11:78.</a></li><li><a class="nounderline abstract_t">Lind L, Jacobsson S, Palmér M, et al. Cardiovascular risk factors in primary hyperparathyroidism: a 15-year follow-up of operated and unoperated cases. J Intern Med 1991; 230:29.</a></li><li><a class="nounderline abstract_t">Kanbay M, Isik B, Akcay A, et al. Relation between serum calcium, phosphate, parathyroid hormone and 'nondipper' circadian blood pressure variability profile in patients with normal renal function. Am J Nephrol 2007; 27:516.</a></li><li><a class="nounderline abstract_t">Maitland ML, Bakris GL, Black HR, et al. Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors. J Natl Cancer Inst 2010; 102:596.</a></li><li><a class="nounderline abstract_t">Jurca SJ, Elliott WJ. Common Substances That May Contribute to Resistant Hypertension, and Recommendations for Limiting Their Clinical Effects. Curr Hypertens Rep 2016; 18:73.</a></li><li><a class="nounderline abstract_t">Rao VU, Reeves DJ, Chugh AR, et al. Clinical Approach to Cardiovascular Toxicity of Oral Antineoplastic Agents: JACC State-of-the-Art Review. J Am Coll Cardiol 2021; 77:2693.</a></li></ol></div><div id="topicVersionRevision">Topic 3862 Version 31.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18574054" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3872106" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Apparent prevalence of curable hypertension in the Hypertension Detection and Follow-up Program.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20864945" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Renovascular hypertension and ischemic nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/503132" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Prevalence of renovascular hypertension in patients with grade III or IV hypertensive retinopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8028081" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Epidemiologic and clinical comparison of renal artery stenosis in black patients and white patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12218965" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Prevalence of renovascular disease in the elderly: a population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2022411" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Similar prevalence of renovascular hypertension in selected blacks and whites.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21963765" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : 2011 ACCF/AHA Focused Update of the Guideline for the Management of Patients With Peripheral Artery Disease (updating the 2005 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25138644" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : SCAI expert consensus statement for renal artery stenting appropriate use.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19666661" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Renal artery revascularization improves heart failure control in patients with atherosclerotic renal artery stenosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11136955" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : The pathogenesis of acute pulmonary edema associated with hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21406441" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Flash pulmonary oedema and bilateral renal artery stenosis: the Pickering syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24074824" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : High-risk clinical presentations in atherosclerotic renovascular disease: prognosis and response to renal artery revascularization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7563536" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : The rational clinical examination. Is listening for abdominal bruits useful in the evaluation of hypertension?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35708012" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Revascularization for Renovascular Disease: A Scientific Statement From the American Heart Association.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34657442" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Screening Rates for Primary Aldosteronism Among Individuals With Hypertension Plus Hypokalemia: A Population-Based Retrospective Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34798068" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Diagnosis and treatment of primary aldosteronism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34843971" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Screening Rate for Primary Aldosteronism Among Patients With Apparent Treatment-Resistant Hypertension: Retrospective Analysis of Current Practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15925740" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Validity of plasma aldosterone-to-renin activity ratio in African American and white subjects with resistant hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14732721" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Resistant hypertension, obesity, sleep apnea, and aldosterone: theory and therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11725173" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : High prevalence of unrecognized sleep apnoea in drug-resistant hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18702977" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Sleep apnea and cardiovascular disease: an American Heart Association/American College of Cardiology Foundation Scientific Statement from the American Heart Association Council for High Blood Pressure Research Professional Education Committee, Council on Clinical Cardiology, Stroke Council, and Council on Cardiovascular Nursing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18997169" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : ACC/AHA 2008 Guidelines for the Management of Adults with Congenital Heart Disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to develop guidelines on the management of adults with congenital heart disease).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23817082" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3338842" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Effects of thyroid function on blood pressure. Recognition of hypothyroid hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2066709" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Cardiovascular risk factors in primary hyperparathyroidism: a 15-year follow-up of operated and unoperated cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17703091" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Relation between serum calcium, phosphate, parathyroid hormone and 'nondipper' circadian blood pressure variability profile in patients with normal renal function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20351338" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27671491" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Common Substances That May Contribute to Resistant Hypertension, and Recommendations for Limiting Their Clinical Effects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34045027" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Clinical Approach to Cardiovascular Toxicity of Oral Antineoplastic Agents: JACC State-of-the-Art Review.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
